Fox Jonathan C. - 16 Jun 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
18 Jun 2025, 19:36:55 UTC
Prior SEC filing
03 Apr 2025
Next SEC filing
02 Jul 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John R. Moore, Attorney-in-Fact for Fox Jonathan C

Key filing fact

Fox Jonathan C. filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 18 Jun 2025.

Key facts

  • This page summarizes Fox Jonathan C.'s Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 18 Jun 2025, 19:36.

Change

  • Previous filing in this sequence was filed on 03 Apr 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001655016 Primary reporting owner

Fox Jonathan C

Relationship
Director
Address
C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER
Signature
/s/ John R. Moore, Attorney-in-Fact for Fox Jonathan C
Signature date
18 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EWTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+30,000
Change %
Price
$0.000000
Shares after
30,000
Date
16 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$14.68
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .